The Role of DPP-4 Inhibitors in Diabetological Care

Abstract

Diabetes mellitus type 2 is the most important medical problem in many countries within the world. The features of hypoglycemic drug with high efficiency include the effectivity, safety, usability, ability to prevent progressive deterioration of pancreatic β-cell function under long-term treatment conditions, and positive impact on the outcomes of diabetes. Inhibitors of dipeptidyl peptidase-4 (DPP-4) belong to the class of glucose reducing drugs which has proved the existence of the potential benefit for clinical diabetology in 10 years. The development of incretinomimetics led to changes in national and international recommendations for the therapy of diabetes. Vildagliptin is included to the family of DPP-4 inhibitors which is widely used in many countries among the world for more than 10 years, although it was introduced inside Ukrainian market only in September 2018 (GLIPTAR, production of Kyivmedpreparat). International clinical trials have shown the great potential of the therapy with vildagliptin which can be characterized by the effectivity either the safety, and it may be stipulated by achievement of glycemic control without complications and other side effects. The advantages of Vildagliptin mono-therapeutic strategy compared to the traditional drugs provide the opportunity to be recommended for initiating therapy of 2 type of diabetes. The validated combination of vildagliptin with other glucose-lowering drugs allows to health care specialists to comprehensively build the treatment approach for all stages of the exacerbation of type 2 diabetes therapy.